

PERSISTENT CV RISK BEYOND LDL-C

Case examples from 2021 CCS Lipid Guidelines

Scientific Planning Committee

André Bélanger

MD CFPC
Shannon, QC

Alice Cheng

MD FRCPC
Toronto, ON

Milan Gupta

MD, FRCPC, FCCS
Brampton, ON

Robert Hegele

MD, FRCPC, Cert Endo,
FACP, FAHA, FCAHS, FCCS
London, ON

Peter Lin

MD, CCFP
Toronto, ON

Laura Reardon

MD
Halifax, NS

This program reviews the latest guideline-based evidence and recommendations regarding lipid markers of risk beyond LDL-cholesterol.

Program Objectives

Upon completion of this program, participants will be able to:

1. Discuss the changes in the management of LDL-C in the 2021 CCS lipid guidelines
2. Determine when to use non-HDL-C, apoB and Lp(a) for risk assessment
3. Utilize triglycerides as a marker of persistent cardiovascular risk beyond LDL-C and implement appropriate management strategies

Program Details and Registration

Speaker Name:

Date:

Time:

Location:

RSVP for live the session:

Rep Name:

Rep Email:

Accreditation

This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College's _____ Chapter.

This program was developed by CCRN and received an educational grant from HLS Therapeutics Inc.

